Autopsy report · NCT00303836
Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma
Cause of deathNo reason given
Life of this trial
- Registered 4 months after it had already started.
- 58 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Recurrent Melanoma; Stage IV Melanoma
- Interventions
- cyclophosphamide; fludarabine phosphate; therapeutic autologous lymphocytes; in vitro-treated peripheral blood stem cell transplantation; gp100 antigen; MART-1 antigen
- Participants
- 58
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.